Under such outcomes-based arrangements, a health plan is eligible to receive an added discount from a pharmaceutical company if a medication is not as effective as was shown in clinical trials.
The survey, which Avalere fielded to 42 U.S. health plans representing 161 million people, found there is particularly strong interest among insurers for outcomes-based arrangements for hepatitis C and oncology drugs.
According to the survey, most of the interest for outcomes-based drugs among health plans centered on expensive specialty drugs. Sixty-three percent of health plans had strong interest in outcomes-based contracts for hepatitis C treatment, 53 percent were interested in such contracts for oncology medicines, 41 percent for rheumatoid arthritis drugs and 35 percent for multiple sclerosis treatments, according to STAT.
Interest in outcomes-based contracts for expensive drugs is “dramatically accelerating right now because the data is available, and it’s getting much easier to track drug performance,” said Dan Mendelson, president of Avalere Health. “In fact, more plans are starting to demand it.”
More articles on payer issues:
Highmark Health looks to sell $1.65B vision unit
United, UNMH split on Medicaid patients, cite reimbursement issues
4 ways HHS is targeting young adults to enroll in ACA exchanges
